checkAd

Angle PLC Announces Issue of Equity - Seite 2

ANGLE's Parsortix® system is FDA cleared for its intended use in metastatic breast cancer and is currently the first and only FDA cleared medical device to harvest intact circulating cancer cells from blood.

Intended use

The Parsortix® PC1 system is an in vitro diagnostic device intended to enrich circulating tumor cells (CTCs) from peripheral blood collected in K2EDTA tubes from patients diagnosed with metastatic breast cancer. The system employs a microfluidic chamber (a Parsortix cell separation cassette) to capture cells of a certain size and deformability from the population of cells present in blood. The cells retained in the cassette are harvested by the Parsortix PC1 system for use in subsequent downstream assays. The end user is responsible for the validation of any downstream assay. The standalone device, as indicated, does not identify, enumerate or characterize CTCs and cannot be used to make any diagnostic/prognostic claims for CTCs, including monitoring indications or as an aid in any disease management and/or treatment decisions.

The Parsortix system enables a liquid biopsy (a simple blood test) to be used to provide the circulating metastatic breast cancer cells to the user in a format suitable for multiple types of downstream analyses. The system is based on a microfluidic device that captures cells based on a combination of their size and compressibility. The system is epitope independent and can capture all phenotypes of CTCs (epithelial, mesenchymal and EMTing CTCs) as well as CTC clusters in a viable form (alive). CTCs harvested from the system enable a complete picture of a cancer to be seen; as being an intact cell they allow DNA, RNA and protein analysis as well as cytological and morphological examination and may provide comparable analysis to a tissue biopsy in metastatic breast cancer. Because CTC analysis is a non-invasive process, unlike tissue biopsy, it can be repeated as often as needed. This is important because cancer develops and changes over time and there is a clear medical need for up-to-date information on the status of a patient's tumor. In addition, the live CTCs harvested by the Parsortix system can be cultured, which offers the potential for testing tumor response to drugs outside the patient.

Seite 2 von 4


Wertpapier



0 Kommentare
Nachrichtenquelle: Accesswire
 |  110   |   |   

Schreibe Deinen Kommentar

Disclaimer

Angle PLC Announces Issue of Equity - Seite 2 Exercise of Options and Total Voting RightsGUILDFORD, SURREY / ACCESSWIRE / September 30, 2022 / ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, announces that following the exercise of employee options, it has issued and …

Nachrichten des Autors

152 Leser
144 Leser
132 Leser
128 Leser
124 Leser
548 Leser
272 Leser
264 Leser
248 Leser
192 Leser
964 Leser
828 Leser
748 Leser
696 Leser
664 Leser
4532 Leser
2851 Leser
1735 Leser
1381 Leser
1280 Leser